Quince Therapeutics, Inc.

Analysis for Ticker: QNCX

Quince Therapeutics Inc is a company that attempts to treat rare brain and muscle diseases like Ataxia-Teleangiectasia by encapsulating drugs inside a patient's own red blood cells to improve delivery and reduce toxicity. The biological reality of this business died in 01/2026 when its lead drug candidate, eDSP, failed its most important clinical trial. The company exists primarily as a decaying organism sustaining a specific ecosystem of financial creditors and insiders who are extracting the last drops of value from the structure. The math is a disaster because the company has lost 460,5 million$ over its lifetime and has no medicine left to sell. The remaining capital is merely consumed to pay the insiders who orchestrated the drain.